Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter (NYSE:BAX) announced on January 13, 2026 the U.S. launch of the Dynamo Series smart stretcher, now available for order and expected to be available during H1 2026. Designed for ED, perioperative and transport use, the Dynamo Series aims to reduce patient transfers with integrated stirrups and a full electric suite for powered drive and positioning. Safety features include Baxter's SafeView+ visual cues, a three-mode bed-exit alarm with auto-rearm, and optional wireless connectivity for EMR and Voalte nurse-call integration. The product offers one of the widest care surfaces in its category and select geographic expansion is planned later in 2026.
MUSC Health and Baxter (NYSE:BAX) announced a multi-year strategic partnership on January 8, 2026 to integrate connected care technologies across MUSC Health’s system.
The collaboration aims to standardize bedside technologies, reduce documentation time, streamline communication, improve nurse satisfaction and retention, enhance quality and safety via real-time insights and advanced monitoring, and support nursing education and scalable best-practice sharing.
Baxter (NYSE:BAX) will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026. Andrew Hider, president and chief executive officer, is scheduled to present at 2:15 p.m. Pacific Time. A live webcast will be available at www.baxter.com and replay access runs through Saturday, July 11, 2026. Investors can watch the live stream or view the replay for Baxter's strategic update and remarks.
Baxter (NYSE:BAX) and The University of Texas Medical Branch presented retrospective analyses of 1.3 million IV infusions using Spectrum IQ large volume pumps, showing improvements after smart pump–EMR integration at six UTMB hospitals over three years (presented at ASHP Dec 7–10, 2025).
Key results: DERS hard alerts -50.3%, soft alerts -30.4%, SSRC alerts -38.1%; median programming time fell from 10s to 4s; alert-resolution times fell ~50% (soft) and 55% (SSRC).
Baxter (NYSE:BAX) announced pricing and terms for cash tender offers for its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. Key figures per $1,000 principal: $990.50 for 2026 notes and $976.61 for 2027 notes; an $30 early tender payment applies.
The 2026 notes outstanding total $750.0M; 2027 notes outstanding total $1,450.0M. The company set a $600M Maximum Tender Cap for 2027s, causing pro rata acceptance of ~56%, and intends to accept $614.37M aggregate principal of 2027 notes for early settlement on Dec. 8, 2025. Total Consideration was determined Dec. 4, 2025 at 10:00 a.m. ET.
Baxter (NYSE:BAX) announced early tender results for its cash offers to repurchase its 2.600% senior notes due 2026 and 1.915% senior notes due 2027. As of the Early Tender Date of Dec. 3, 2025, holders validly tendered $420,589,000 of 2026 Notes and $1,088,660,000 of 2027 Notes against outstanding amounts of $750,000,000 and $1,450,000,000, respectively.
Baxter elected early settlement on Dec. 8, 2025. Total consideration will be set at 10:00 a.m. ET on Dec. 4, 2025 and includes an early tender payment of $30 per $1,000 principal. The company capped purchases of 2027 Notes at $600 million, so accepted 2027 tenders will be pro rated and the company does not expect to accept 2027 tenders after the Early Tender Date.
Baxter (NYSE:BAX) increased the maximum repurchase cap for its 1.915% Senior Notes due 2027 from $300 million to $600 million under its previously announced cash tender offer, for an aggregate $1.45 billion outstanding of those notes. The terms for the separate 2.600% Senior Notes due 2026 tender offer remain unchanged. The Offer to Purchase dated Nov. 19, 2025 governs the Tender Offers, including the applicable portion of the Financing Condition as modified by this press release. Citigroup, BofA Securities and J.P. Morgan are dealer managers; D.F. King is tender and information agent. This press release is not an offer to purchase securities.
Baxter (NYSE:BAX) commenced tender offers on Nov. 19, 2025 to purchase its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027.
The company will fund the offers subject to conditions using proceeds from a concurrent offering of new senior unsecured notes, and intends to use remaining proceeds to repay other indebtedness, including a term loan that had a $645 million outstanding balance as of Sept. 30, 2025.
Key dates: Early Tender Date Dec. 3, 2025; Price Determination Date Dec. 4, 2025; Expiration Dec. 18, 2025; anticipated settlement Dec. 22, 2025.
Baxter (NYSE:BAX) announced a quarterly cash dividend of $0.01 per share, payable on Jan. 2, 2026 to holders of record as of Nov. 28, 2025. The company said the indicated annual dividend rate is $0.04 per share. Management confirmed the reduction in the quarterly dividend will begin in January 2026 and is expected to free up more than $300 million in annual cash flow to accelerate deleveraging.
Baxter Foundation (NYSE:BAX) announced a $2.6 million, three-year grant to continue its partnership with Northwestern University School of Education and Social Policy to support the Baxter Center for Science Education (BCSE) in Chicagoland.
The funding sustains educator professional development, classroom lab supplies and student STEM experiences. Since 2009 the Foundation has provided nearly $9 million to the BCSE, which has reached about 260,000 students and trained nearly 4,000 teachers across 400+ schools in Cook and Lake counties.